Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11
Zentalis Pharmaceuticals Inc ZNTL
$4.74
▼ -3.66%
($-0.18)
📅 Earnings This Week
Open
$4.95
Prev Close
$4.92
Day Range
$4.66 – $4.99
52W Range
$1.21 – $6.95
Market Cap
$350.24M
Beta
1.92
EPS (TTM)
$-1.91
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-04-03 |
| Shares Out. | 71,190,000 |
| Website | zentalis.com/ ↗ |
| Phone | 18582634333 |
| Employees | 106 |
| Net Income | -$35.4M |
| Free Cash Flow | -$125.6M |
| Total Assets | $253.1M |
| Total Liabilities | $70.4M |
| Equity | $182.7M |
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Zentalis Pharmaceuticals Inc is a publicly traded company under the ticker symbol ZNTL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)